[1]naphthyl-methanesulfonic acid | 132-78-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [1]naphthyl-methanesulfonic acid
• 英文别名: [1]Naphthyl-methansulfonsaeure；naphthylmethanesulphonate；Naphthalen-1-ylmethanesulfonic acid
• CAS: 132-78-5
• 化学式: C₁₁H₁₀O₃S
• 分子量: 222.265
• InChiKey: AKBIVIMPMQGECH-UHFFFAOYSA-N

物化性质

• 密度：
  1.403±0.06 g/cm3(Predicted)
• 熔点：
  247-248 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  萘 在 盐酸 、 zinc(II) chloride 、 sodium sulfite 、 Petroleum ether 作用下， 生成 [1]naphthyl-methanesulfonic acid
  参考文献：
  名称：

  119.氯甲基萘和1：5-二甲基萘的制备

  摘要：

  DOI：

  10.1039/jr9330000485

文献信息

• METHOD FOR PREPARING COAGULATION FACTOR XIA INHIBITOR AND INTERMEDIATE THEREOF
  申请人：JIANGSU HENGRUI MEDICINE CO., LTD.

  公开号：US20210292279A1

  公开（公告）日：2021-09-23

  The present disclosure involves a method for preparing a coagulation factor XIa inhibitor and an intermediate thereof. Specifically, the present disclosure involves a method for preparing an oxypyridine amide derivative. The method has the advantages of high yield, good product purity, and mild reaction conditions.

  本公开涉及一种制备凝血因子XIa抑制剂及其中间体的方法。具体而言，本公开涉及一种制备氧吡啶酰胺衍生物的方法。该方法具有高产率、良好的产品纯度和温和的反应条件的优点。
• [EN] QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSÉ DE QUINOLONE ET AGENT PHARMACEUTIQUE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010064735A1

  公开（公告）日：2010-06-10

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，以便在延长给予L-多巴的时间的同时改善神经元功能；本发明的喹诺酮化合物由公式(1)表示：其中：R1代表氢等；R2代表氢等；R3代表取代或未取代的苯基等；R4代表卤素等；R5代表氢等；R6代表氢等；R7代表氢等。
• [EN] PIPERAZINE- SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DÉRIVÉS DE BENZOTHIOPHÈNE SUBSTITUÉ PAR PIPÉRAZINE EN TANT QU'AGENTS ANTIPSYCHOTIQUES
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2013035892A1

  公开（公告）日：2013-03-14

  Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种优越的、新颖的杂环化合物，其在油中的溶解性得到改善，如芝麻油和苯基苯甲酸酯，具有更广泛的治疗范围，引起的副作用更少，在耐受性和安全性方面更为优越，以及其使用。表示为式(I)的杂环化合物，其中每个符号如规范中定义的，或其盐。
• Use of metal complex compounds as catalysts for oxidation using molecular oxygen or air
  申请人：Wieprecht Torsten

  公开号：US20060019853A1

  公开（公告）日：2006-01-26

  Use, as a catalyst for oxidation reactions using molecular oxygen and/or air, of at least one metal complex compound of formula (1) wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, Y is a counter-ion, q=z/(charge of Y), and L is a ligand of formula (2) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are each independently of the others hydrogen; unsubstituted or substituted C 1 -C 18 alkyl or aryl; cyano; halogen; nitro; —COOR 12 or —SO 3 R 12 wherein R 12 is in each case hydrogen, a cation or unsubstituted or substituted C 1 -C 18 alkyl or aryl; —SR 13 , —SO 2 R 13 or —OR 13 wherein R 13 is in each case hydrogen or unsubstituted or substituted C 1 -C 18 alkyl or aryl; —NR 14 R 15 ; —(C 1 -C 6 alkylene)-NR 14 R 15 ; —N (+) R 14 R 15 R 16 ; —(C 1 -C 6 alkylene)-N (+) R 14 R 15 R 16 ; —N(R 13 )—(C 1 -C 6 alkylene)-NR 14 R 15 ; —N[(C 1 -C 6 alkylene)-NR 14 R 15 ] 2 ; —N(R 13 )—(C 1 -C 6 alkylene)-N (+) R 14 R 15 R 16 ; —N[(C 1 -C 6 alkylene)-N (+) R 14 R 15 R 16]2 ; —N(R 13 )—N—R 14 R 15 or —N(R 13 )N″R 14 R 15 R 16 , wherein R 13 is as defined above and R 14 , R 15 and R 16 are each independently of the other(s) hydrogen or unsubstituted or substituted C 1 -C 18 alkyl or aryl, or R 14 and R 15 , together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms. [L n Me m X p ] z Y q (1)

  使用至少一种具有以下式（1）的金属配合物化合物作为氧化反应的催化剂，其中Me为锰、钛、铁、钴、镍或铜，X为配位或桥联基团，n和m分别独立地为1至8之间的整数，p为0至32之间的整数，z为金属配合物的电荷，Y为对离子，q=z/(Y的电荷)，L为具有以下式（2）的配体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11各自独立地为氢；未取代或取代的C1-C18烷基或芳基；氰基；卤素；硝基；—COOR12或—SO3R12，其中R12在每种情况下为氢、阳离子或未取代或取代的C1-C18烷基或芳基；—SR13、—SO2R13或—OR13，其中R13在每种情况下为氢或未取代或取代的C1-C18烷基或芳基；—NR14R15；—(C1-C6烷基)-NR14R15；—N(+)R14R15R16；—(C1-C6烷基)-N(+)R14R15R16；—N(R13)—(C1-C6烷基)-NR14R15；—N[(C1-C6烷基)-NR14R15]2；—N(R13)—(C1-C6烷基)-N(+)R14R15R16；—N[(C1-C6烷基)-N(+)R14R15R16]2；—N(R13)—N—R14R15或—N(R13)N″R14R15R16，其中R13如上定义，R14、R15和R16各自独立地为氢或未取代或取代的C1-C18烷基或芳基，或R14和R15与连接它们的氮原子一起形成未取代或取代的5、6或7成员环，该环可能含有进一步的杂原子。[LnMemXp]zYq（1）
• [EN] DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF<br/>[FR] DÉRIVÉS DE DÉCAHYDROQUINOXALINE ET LEURS ANALOGUES
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2013137479A1

  公开（公告）日：2013-09-19

  A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH2-; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

  通用式（1）表示的杂环化合物或其盐：其中m，l和n分别表示1或2的整数；X表示-O-或-CH2-；R1表示氢，较低的烷基基团，羟基较低的烷基基团，保护基或三较低烷氧基较低的烷基基团；R2和R3，相同或不同，各自独立地表示氢或较低的烷基基团；或R2和R3结合形成环-C3-C8烷基基团；R4表示芳香基团或杂环基团，其中芳香基团或杂环基团可能具有一个或多个任意取代基。